Metabolic Characterization of Space Occupying Lesions of the Brain

High field MR-technologies are expected to boost metabolic spectroscopic imaging (MRSI), but also CEST-MRI. This is due to the fact that increased SNR is available which can be used to increase the spatial resolution of all sequences, or reduction of measurement times. Recent findings has shown that MRSI can be used to evaluate the isocitrate dehydrogenase (IDH) status of gliomas, a brain tumor type which is most often diagnosed in humans. Patients with IDH-mutated gliomas have a much longer survival time that IDH-wildtype. In IDH-mutated gliomas the substance 2-hydroxy-glutarate (2HG) is found, whereas in IDH-wildtype gliomas it is not.

The underlying trial aims to measure 2HG directly with different MRSI sequences at 3 Tesla (3T) and 7 Tesla (7T) magnetic field strength. Apart from MRSI-techniques for IDH-typing it has been shown that CEST-imaging can also be performed to determine the IDH-status of gliomas.

A total of 75 patients and 50 healthy controls will be examined in this study to evaluate the most accurate method for pre-operative IDH-status determination.

Introduction - Recently the first commercially available 7T MR-scanner which is approved for clinical use came on to the market. The main motivation to go to higher field strengths is the fact that better SNR can be achieved in shorter acquisition time, or higher spatial resolution can be obtained in the same measurement time. High field MRI also has drawbacks, e.g. substantially higher specific absorption rate (SAR), higher susceptibility related image distortion problems, and longer longitudinal relaxation times. Nevertheless, moving to higher fields is especially beneficial for MR-spectroscopy. This is due to the fact that better signal to noise ration (SNR) is combined with higher spectral resolution. The two most commonly used techniques for spectroscopic imaging (MRSI) are: (i.) relative slow 2D/3D techniques like PRESS and semiLASER based techniques, and (ii.) fast 3D echo planar based (EPI) techniques. Although echo planar spectroscopic imaging (EPSI) is a technique that has been introduced by Sir Peter Mansfield in the first half of 80es, the method is still continuously being improved, and recently very promising applications related to brain tumor diagnostics were published. To be mentioned in this context is the fact that the method can be combined with spectral editing for the detection of 2-hydroxy-glutarate (2HG) in glioma patients. 2HG is only present if the glioma that has mutations in the IDH-gene. It is shown that gliomas having the IDH-mutation have a much better overall survival prognosis. Apart from brain tumor typing, high resolution EPSI imaging also enables investigation the investigation of tumor infiltration using metabolic criteria. In surgery the patients' preoperative intake of the 5-aminolevulinic acid (5-ALA) before surgery selectively makes malignant glioma tissues fluorescent under blue light irradiation and tumor itself becomes clearly visible during the neurosurgical intervention. The fact that 5-ALA-guided completely-resected glioma patients have a significant longer survival time, underlines the necessity to know the exact tumor boundaries.

Aims - The major aims of the study proposed are manifold:

(i.) The development of a novel EPSI-pulse sequence utilizing 3D-radial k-space sampling schemes, that focuses on robustness w.r.t. patient motion, is robust with respect to chemical shift displacement artifacts, includes the possibility of 2HG-spectral editing, uses SAR-reduced radiofrequency (RF) pulses, and operate with total acquisition times that are acceptable for clinical routine use; (ii.) Comparison of the novel sequence with available conventional EPSI-techniques and semiLASER-based techniques for clinical routine use comparing its performance at 3T and 7T; (iii.) The development of a graphic processor unit (GPU) based fitting algorithm for quantification of 3D-radial EPSI-data based on the existing tdfdfit-algorithm; (iv.) Extension of a locally developed machine learning based automatic quality-filtering algorithm to be applied on the researchers' novel EPSI-data; (v.) Quantitative investigation on the effect spatial non-uniform transmit and receive properties for all relevant metabolites and spatial dependent signal amplitude correction schemes (extension of a locally developed method); (vi.) Investigation of the exact effects of selective excitation on J-coupled spin systems, and comparison of these effects between 3T and 7T; (vii.) Reproducibility study on 20 healthy volunteers measured twice with the same protocol (10 recorded twice at 7T and 10 recorded twice at 3T); (viii.) Pre-operative application of the best suited EPSI-pulse sequence in a total of 75 patients. All patients will be recorded at 3T as well as at 7T using the equivalent protocols; (ix.) Co-registration of pre-operative, spatially resolved 3D-EPSI-MRSI data with post-operative 3D-FLAIR and T1c-imaging in IDH-wildtype patients with had complete resection during 5-ALA guided neurosurgical interventions will provide information on whether MRSI-techniques are helpful to predict the tumor affected volume; (x.) Documentation of the location of a biopsy, histology to enable a better correlation between MR-spectroscopic patterns and histology.

(xi) Comparison of the performance of CEST versus the CMRR-semiLASER MRSI sequence w.r.t. to the prediction accuracy of the IDH-type of the glioma by the two technologies.

Methodology - The implementation of a robust EPSI sequence that uses 3D-radial k-space sampling schemes and reconstruction will be performed on Siemens IDEA developer platforms for VE- and XA-software versions. The sequence will be compared to the performance obtained with another EPSI implementation, available via Siemens, as well as the CMRR-implementation of the MEGA (MEscher-GArwood) semi-LASER (Localization by Adiabatic SElective Refocusing) for 2HG-editing (CMRR Spectroscopy Package, 2012). The quantification of the EPSI-data of the reference sequence will be performed with the MIDAS package. The EPSI-data of the novel sequence as well as MEGA-semi-LASER sequence will be quantified using a parallelized GPU-re-implementation of the tdfdfit-algorithm made available as separate plugin within jMRUI-spectroscopy package (jMRUI: java magnetic resonance user interface). Co-registration of pre-surgery EPSI-data with post-operative structural MRI-data will be performed with the SPM (Statistical Parameter Mapping) program. Further statistical analysis and machine learning algorithms will be based on statistical programming language "R". The CEST pulse sequences will be obtained via Siemens-Healthineers.

Potential significance - (a.) Pre-surgical knowledge of the IDH-status will enable better individual neurosurgical treatment of the patient; (b.) Coregistration of metabolic EPSI-data, with post-operative structural MR-data will give information on the fundamental usefulness of MRSI-techniques to detect glioma infiltration zones; (c.) Improved follow-up of IDH-mutated glioma patients, who typically have a long period of minimal progression, followed rapidly by aggressive growth and transformation to higher grade; (d.) The availability of an imaging biomarker to monitor tumor recurrence would be a major advance for all glioma patients.

Eligibility Criteria:
Inclusion Criteria:

* Healthy people who are able to lie in the MR scanner for one hour;
* Patients with suspected mass in the brain
* Written informed consent

Exclusion Criteria:

* Persons under the age of 18
* Persons who are mentally unable to choose to participate
* Pregnant women
* Patients with oncological findings or neurodegenerative findings in the past
* Wearing active implants (e.g. pacemakers and neurostimulators)
* Emergency patients
* Persons with tattoos on the head or neck area